At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 269 enrolled
Drug / intervention
Fampridine-SRdrug
Likely dose
Fampridine-SR 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial
In Brief
A Phase 3 clinical trial evaluating Fampridine-SR for Multiple Sclerosis. Completed, enrolled 269 participants across 32 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who previously participated in Acorda Therapeutics Protocol MS-F203.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedApr 2008
Primary CompletionJan 2011
Study CompletionApr 2011
TodayJul 2026
First PostedApr 1, 2008
Enrollment StartJun 1, 2006
Primary CompletionJan 1, 2011
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.3 years ago
Interventions
Fampridine-SRdrug
Tablets, 10 mg, BID